Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003298 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
A Phase 2 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00003298: Completed Phase 2 study, sponsored by ECOG-ACRIN Cancer Research Group.
NCT00003298 is a Phase 2 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003298, a Phase 2 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells. E7296 was conducted to study neoadjuvant chemotherapy and postoperative chemoradiation therapy in patients diagnosed with high-risk gastric cancer using a new neoadjuvant regimen: paclitaxel plus cisplatin. It was hypothesized that this new neoadjuvant chemotherapy followed by surgery and chemoradiation therapy would be well tolerated and would have a high curative resection rate.
Primary Outcome
Incidence is defined as proportion of patients with any grade 3 or higher treatment-related toxicities among all treated patients.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG fluorouracil
- DRUG leucovorin calcium
- PROCEDURE surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1999-06-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
What the finished NCT00003298 record still lists
NCT00003298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003298 about?
NCT00003298 is a clinical study titled "Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells. E7296 was conducted to study neoa...
What is the current status of trial NCT00003298?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 1999-06-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00003298?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00003298?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003298's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI